GTC Biotherapeutics (fka GTCB)

[dewophile]

"How will this longer half life be accomplished?

Geoffrey Cox

Well, actually, I can't answer you the question to that because that's sort of work in progress, to be quite honest. And so, that's still sort of a proprietary situation"

thanks for the transcript and this question during the cc. Aside from implications to AAT per se, its clear GTCB has yet another platform technology to add value in the FOB arena. It's early imo to put serious money in FOBs, but GTCB certainly seems poised as a future player with this three-pronged platform (cost advantages, enhanced ADCC, pK tweaking)

PS: my guess is pk modifications, like ADCC, involve modifications in glycosylation